Status:
COMPLETED
Hepatic Arterial Infusion (HAI) of Abraxane
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborating Sponsors:
National Comprehensive Cancer Network
Conditions:
Liver Cancer
Advanced Cancers
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The goal of this clinical research study is find the highest tolerated dose of Abraxane (nab-paclitaxel) that can be given directly into the liver of patients with advanced cancer that has spread to t...
Detailed Description
The Study Drug: Nab-paclitaxel is designed to block cancer cells from dividing, which may cause the cells to die. Giving nab-paclitaxel directly into the liver may allow a higher dose of the drug to...
Eligibility Criteria
Inclusion
- Pathologically confirmed diagnosis of advanced malignancy and liver involvement as predominant site of metastasis.
- An Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
- Adequate end-organ function as follows: Absolute neutrophil count (ANC) \> or = 1500/mm3, Platelets \> or = 100,000/mm3, Creatinine \< or = 2.0 mg/dL or the calculated Glomerular filtration rate (GFR) \> or = 40 mL/min if Creatinine \> 2.0 mg/dL, ALT \< or = 5 times upper limits of normal, Hb \> 9.0 and Bilirubin \< or = 2.0 mg/dL.
- Refractory to standard cancer therapy or who have no conventional therapy that produces a complete response rate of at least 10% or an increase in survival of at least 3 months.
- Ability to fully comprehend and willingness to sign the Institutional Review Board (IRB) approved informed consent
- Full recovery from any previous therapy and ability to receive cytotoxic agents.
- Patient is 18 years of age or older
Exclusion
- Clinically significant ascites.
- Pregnant or breastfeeding females. Women of childbearing potential should be advised to avoid becoming pregnant and men to not father a child while receiving treatment. Women of childbearing potential must have a negative pregnancy test.
- Hypersensitivity to Abraxane
- Untreatable bleeding diathesis
- Evidence of portal vein thrombosis and clinically significant peripheral vascular disease
- Neuropathy of grade 2 or higher
- A known history of central nervous system (CNS) metastasis unless the patients are neurologically stable after treatment with surgery and/or radiation therapy
- If the patient progressed on abraxane previously they will not be eligible for the dose escalation portion or the PK studies only. These patients can be included in the dose expansion portion of the trial.
Key Trial Info
Start Date :
June 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2016
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT00732836
Start Date
June 1 2008
End Date
January 1 2016
Last Update
February 5 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030